Hepatitis B virus infection and hepatocellular carcinoma among parous taiwanese women: Nationwide cohort study

Chyng Wen Fwu, Yin Chu Chien, Gregory D Kirk, Kenrad Edwin Nelson, San Lin You, Hsu Sung Kuo, Manning Feinleib, Chien Jen Chen

Research output: Contribution to journalArticle

Abstract

BackgroundFew long-term studies of hepatitis B virus (HBV) infection and hepatocellular carcinoma have focused on women. We used a nationwide cohort of reproductive-aged Taiwanese women to study relationships of HBV infection and parity with hepatocellular carcinoma risk.MethodsPrenatal test results were available for hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in the National Hepatitis B Vaccination Registry from 1782401 pregnant women tested from October 1, 1983, through March 31, 2000. Data from the 306 women who were diagnosed with hepatocellular carcinoma were ascertained during 15901722 person-years of follow-up through linkage with National Cancer Registry and National Death Certification Registry. We used Cox proportional hazards models to investigate the association of age and reproductive and serological parameters with the risk of hepatocellular carcinoma.ResultsIncidence rates for hepatocellular carcinoma were 0.55, 7.91, and 8.76 per 100000 person-years among women who were HBsAg negative (ie, noncarriers), HBsAg positive plus HBeAg negative, and HBsAg positive plus HBeAg positive, respectively (compared with noncarriers, for HBsAg-positive and HBeAg-positive women, age-adjusted hazard ratio [HR] for developing hepatocellular carcinoma = 17.31, 95% confidence interval [CI] = 12.08 to 24.81; and for HBsAg-negative plus HBeAg-positive women, HR = 13.94, 95% CI = 10.34 to 18.79). Incidence rates were 0.39, 3.10, and 9.01 per 100000 person-years, respectively, among persistent noncarriers, HBsAg-serocleared carriers, and persistent HBsAg carriers (compared with noncarriers, for HBsAg-serocleared carriers, age-adjusted HR = 7.95, 95% CI = 3.50 to 18.04; and for HBsAg persistence, HR = 23.13, 95% CI = 14.23 to 37.61). Incidence rates were 2.04, 1.55, and 1.66 per 100000 person-years for women who had one, two, or three or more children, respectively (compared with one child, for two children, age- and HBsAg-adjusted HR = 0.68, 95% CI = 0.50 to 0.93; and for three or more children, HR = 0.63, 95% CI = 0.42 to 0.92).ConclusionsThe risk for hepatocellular carcinoma was statistically significantly higher among women with chronic or active HBV infections and among those with persistent HBV infection or who underwent HBsAg seroclearance during follow-up than among HBV-unexposed women. This risk decreased as parity increased, independent of HBsAg status and age.

Original languageEnglish (US)
Pages (from-to)1019-1027
Number of pages9
JournalJournal of the National Cancer Institute
Volume101
Issue number14
DOIs
StatePublished - Jul 2009

Fingerprint

Virus Diseases
Hepatitis B Surface Antigens
Hepatitis B virus
Hepatocellular Carcinoma
Cohort Studies
Hepatitis B e Antigens
Confidence Intervals
Registries
Parity
Incidence
Certification
Chronic Hepatitis
Hepatitis B
Proportional Hazards Models

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hepatitis B virus infection and hepatocellular carcinoma among parous taiwanese women : Nationwide cohort study. / Fwu, Chyng Wen; Chien, Yin Chu; Kirk, Gregory D; Nelson, Kenrad Edwin; You, San Lin; Kuo, Hsu Sung; Feinleib, Manning; Chen, Chien Jen.

In: Journal of the National Cancer Institute, Vol. 101, No. 14, 07.2009, p. 1019-1027.

Research output: Contribution to journalArticle

Fwu, Chyng Wen ; Chien, Yin Chu ; Kirk, Gregory D ; Nelson, Kenrad Edwin ; You, San Lin ; Kuo, Hsu Sung ; Feinleib, Manning ; Chen, Chien Jen. / Hepatitis B virus infection and hepatocellular carcinoma among parous taiwanese women : Nationwide cohort study. In: Journal of the National Cancer Institute. 2009 ; Vol. 101, No. 14. pp. 1019-1027.
@article{e8f71d1de5d94010ae8552b8228451d2,
title = "Hepatitis B virus infection and hepatocellular carcinoma among parous taiwanese women: Nationwide cohort study",
abstract = "BackgroundFew long-term studies of hepatitis B virus (HBV) infection and hepatocellular carcinoma have focused on women. We used a nationwide cohort of reproductive-aged Taiwanese women to study relationships of HBV infection and parity with hepatocellular carcinoma risk.MethodsPrenatal test results were available for hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in the National Hepatitis B Vaccination Registry from 1782401 pregnant women tested from October 1, 1983, through March 31, 2000. Data from the 306 women who were diagnosed with hepatocellular carcinoma were ascertained during 15901722 person-years of follow-up through linkage with National Cancer Registry and National Death Certification Registry. We used Cox proportional hazards models to investigate the association of age and reproductive and serological parameters with the risk of hepatocellular carcinoma.ResultsIncidence rates for hepatocellular carcinoma were 0.55, 7.91, and 8.76 per 100000 person-years among women who were HBsAg negative (ie, noncarriers), HBsAg positive plus HBeAg negative, and HBsAg positive plus HBeAg positive, respectively (compared with noncarriers, for HBsAg-positive and HBeAg-positive women, age-adjusted hazard ratio [HR] for developing hepatocellular carcinoma = 17.31, 95{\%} confidence interval [CI] = 12.08 to 24.81; and for HBsAg-negative plus HBeAg-positive women, HR = 13.94, 95{\%} CI = 10.34 to 18.79). Incidence rates were 0.39, 3.10, and 9.01 per 100000 person-years, respectively, among persistent noncarriers, HBsAg-serocleared carriers, and persistent HBsAg carriers (compared with noncarriers, for HBsAg-serocleared carriers, age-adjusted HR = 7.95, 95{\%} CI = 3.50 to 18.04; and for HBsAg persistence, HR = 23.13, 95{\%} CI = 14.23 to 37.61). Incidence rates were 2.04, 1.55, and 1.66 per 100000 person-years for women who had one, two, or three or more children, respectively (compared with one child, for two children, age- and HBsAg-adjusted HR = 0.68, 95{\%} CI = 0.50 to 0.93; and for three or more children, HR = 0.63, 95{\%} CI = 0.42 to 0.92).ConclusionsThe risk for hepatocellular carcinoma was statistically significantly higher among women with chronic or active HBV infections and among those with persistent HBV infection or who underwent HBsAg seroclearance during follow-up than among HBV-unexposed women. This risk decreased as parity increased, independent of HBsAg status and age.",
author = "Fwu, {Chyng Wen} and Chien, {Yin Chu} and Kirk, {Gregory D} and Nelson, {Kenrad Edwin} and You, {San Lin} and Kuo, {Hsu Sung} and Manning Feinleib and Chen, {Chien Jen}",
year = "2009",
month = "7",
doi = "10.1093/jnci/djp146",
language = "English (US)",
volume = "101",
pages = "1019--1027",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "14",

}

TY - JOUR

T1 - Hepatitis B virus infection and hepatocellular carcinoma among parous taiwanese women

T2 - Nationwide cohort study

AU - Fwu, Chyng Wen

AU - Chien, Yin Chu

AU - Kirk, Gregory D

AU - Nelson, Kenrad Edwin

AU - You, San Lin

AU - Kuo, Hsu Sung

AU - Feinleib, Manning

AU - Chen, Chien Jen

PY - 2009/7

Y1 - 2009/7

N2 - BackgroundFew long-term studies of hepatitis B virus (HBV) infection and hepatocellular carcinoma have focused on women. We used a nationwide cohort of reproductive-aged Taiwanese women to study relationships of HBV infection and parity with hepatocellular carcinoma risk.MethodsPrenatal test results were available for hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in the National Hepatitis B Vaccination Registry from 1782401 pregnant women tested from October 1, 1983, through March 31, 2000. Data from the 306 women who were diagnosed with hepatocellular carcinoma were ascertained during 15901722 person-years of follow-up through linkage with National Cancer Registry and National Death Certification Registry. We used Cox proportional hazards models to investigate the association of age and reproductive and serological parameters with the risk of hepatocellular carcinoma.ResultsIncidence rates for hepatocellular carcinoma were 0.55, 7.91, and 8.76 per 100000 person-years among women who were HBsAg negative (ie, noncarriers), HBsAg positive plus HBeAg negative, and HBsAg positive plus HBeAg positive, respectively (compared with noncarriers, for HBsAg-positive and HBeAg-positive women, age-adjusted hazard ratio [HR] for developing hepatocellular carcinoma = 17.31, 95% confidence interval [CI] = 12.08 to 24.81; and for HBsAg-negative plus HBeAg-positive women, HR = 13.94, 95% CI = 10.34 to 18.79). Incidence rates were 0.39, 3.10, and 9.01 per 100000 person-years, respectively, among persistent noncarriers, HBsAg-serocleared carriers, and persistent HBsAg carriers (compared with noncarriers, for HBsAg-serocleared carriers, age-adjusted HR = 7.95, 95% CI = 3.50 to 18.04; and for HBsAg persistence, HR = 23.13, 95% CI = 14.23 to 37.61). Incidence rates were 2.04, 1.55, and 1.66 per 100000 person-years for women who had one, two, or three or more children, respectively (compared with one child, for two children, age- and HBsAg-adjusted HR = 0.68, 95% CI = 0.50 to 0.93; and for three or more children, HR = 0.63, 95% CI = 0.42 to 0.92).ConclusionsThe risk for hepatocellular carcinoma was statistically significantly higher among women with chronic or active HBV infections and among those with persistent HBV infection or who underwent HBsAg seroclearance during follow-up than among HBV-unexposed women. This risk decreased as parity increased, independent of HBsAg status and age.

AB - BackgroundFew long-term studies of hepatitis B virus (HBV) infection and hepatocellular carcinoma have focused on women. We used a nationwide cohort of reproductive-aged Taiwanese women to study relationships of HBV infection and parity with hepatocellular carcinoma risk.MethodsPrenatal test results were available for hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in the National Hepatitis B Vaccination Registry from 1782401 pregnant women tested from October 1, 1983, through March 31, 2000. Data from the 306 women who were diagnosed with hepatocellular carcinoma were ascertained during 15901722 person-years of follow-up through linkage with National Cancer Registry and National Death Certification Registry. We used Cox proportional hazards models to investigate the association of age and reproductive and serological parameters with the risk of hepatocellular carcinoma.ResultsIncidence rates for hepatocellular carcinoma were 0.55, 7.91, and 8.76 per 100000 person-years among women who were HBsAg negative (ie, noncarriers), HBsAg positive plus HBeAg negative, and HBsAg positive plus HBeAg positive, respectively (compared with noncarriers, for HBsAg-positive and HBeAg-positive women, age-adjusted hazard ratio [HR] for developing hepatocellular carcinoma = 17.31, 95% confidence interval [CI] = 12.08 to 24.81; and for HBsAg-negative plus HBeAg-positive women, HR = 13.94, 95% CI = 10.34 to 18.79). Incidence rates were 0.39, 3.10, and 9.01 per 100000 person-years, respectively, among persistent noncarriers, HBsAg-serocleared carriers, and persistent HBsAg carriers (compared with noncarriers, for HBsAg-serocleared carriers, age-adjusted HR = 7.95, 95% CI = 3.50 to 18.04; and for HBsAg persistence, HR = 23.13, 95% CI = 14.23 to 37.61). Incidence rates were 2.04, 1.55, and 1.66 per 100000 person-years for women who had one, two, or three or more children, respectively (compared with one child, for two children, age- and HBsAg-adjusted HR = 0.68, 95% CI = 0.50 to 0.93; and for three or more children, HR = 0.63, 95% CI = 0.42 to 0.92).ConclusionsThe risk for hepatocellular carcinoma was statistically significantly higher among women with chronic or active HBV infections and among those with persistent HBV infection or who underwent HBsAg seroclearance during follow-up than among HBV-unexposed women. This risk decreased as parity increased, independent of HBsAg status and age.

UR - http://www.scopus.com/inward/record.url?scp=67650815283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650815283&partnerID=8YFLogxK

U2 - 10.1093/jnci/djp146

DO - 10.1093/jnci/djp146

M3 - Article

C2 - 19535774

AN - SCOPUS:67650815283

VL - 101

SP - 1019

EP - 1027

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 14

ER -